Viewing data from:

ACITRETIN

ANDA

ACITRETIN | A202897 | TEVA PHARMACEUTICALS USA

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$5.41

per ea

Lowest NADAC/Unit

$5.41

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00093113856ACITRETIN 17.5 MG CAPSULE	$5.41	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain7 active DMFs2 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

OLON SPAACITRETIN

DMF 170012003

SOLARA ACTIVE PHARMA SCIENCES LTDACITRETIN

DMF 223582008

USV PRIVATE LTDACITRETIN USP

DMF 233102009

OLON SPAACITRETIN (FORM I)

DMF 244302010

CHONGQING HUAPONT PHARMACEUTICAL CO LTDACITRETIN

DMF 246212011

GLOPEC INTERNATIONAL INCACITRETIN

DMF 261822012

SUN PHARMACEUTICAL INDUSTRIES LTDACITRETIN USP

DMF 288962014

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveACITRETIN USP

DMF 165802003

BASF SEInactiveACITRETIN

DMF 220902008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 17.5MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Apr 4, 2013

No patent or exclusivity listings for this strength.

#002 — 22.5MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Apr 4, 2013